相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta-Activated Kinase 1-c-Jun-N-Terminal Kinase/p38 Signaling
Junyong Wang et al.
HEPATOLOGY (2021)
CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma
Guangna Liu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview
Niels Schaft
CANCERS (2020)
CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth
Xiaodong Zhuang et al.
JCI INSIGHT (2020)
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Yushu Joy Xie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Jie Deng et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Targeting Treg cells in cancer immunotherapy
Atsushi Tanaka et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Rachel Grosser et al.
CANCER CELL (2019)
TEM8/ANTXR1-specific CART cells mediate toxicity in vivo
Kristina Petrovic et al.
PLOS ONE (2019)
CXCR1-or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Linchun Jin et al.
NATURE COMMUNICATIONS (2019)
CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
Wanghong Hu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
The success and the challenge of all-trans retinoic acid in the treatment of cancer
Xiaoling Ni et al.
CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION (2019)
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma
Timothy M. Nywening et al.
GUT (2018)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cancer Metabolism: Current Understanding and Therapies
Jessica L. Counihan et al.
CHEMICAL REVIEWS (2018)
A guide to chemokines and their receptors
Catherine E. Hughes et al.
FEBS JOURNAL (2018)
Targeting fibroblast activation protein in cancer - Prospects and caveats
Petr Busek et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2018)
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
Gregory L. Beatty et al.
GASTROENTEROLOGY (2018)
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication
Christopher C. Kloss et al.
MOLECULAR THERAPY (2018)
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
Keishi Adachi et al.
NATURE BIOTECHNOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+Tumor-Mediated Exhaustion
J. Dozier et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer
Tiara T. Byrd et al.
CANCER RESEARCH (2018)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
Elise A. Chong et al.
BLOOD (2017)
Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Jiangtao Ren et al.
CLINICAL CANCER RESEARCH (2017)
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
Frederick Arce Vargas et al.
IMMUNITY (2017)
Oxygen availability and metabolic reprogramming in cancer
Hong Xie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients
Richard P. Tobin et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers
Chengcheng Zhang et al.
MOLECULAR THERAPY (2017)
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Andras Heczey et al.
MOLECULAR THERAPY (2017)
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Somala Mohammed et al.
MOLECULAR THERAPY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Donald M. O'Rourke et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
Jiangtao Ren et al.
PROTEIN & CELL (2017)
Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy
Anne-Sophie Gautron et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Expansion of HER2-CAR T cells after lymphodepletion and clinical responses in patients with advanced sarcoma.
Meenakshi Hegde et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
Fiona C. Thistlethwaite et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
Young-hee Lee et al.
CELL RESEARCH (2017)
Dysfunctional T cell metabolism in the tumor microenvironment
Kathryn E. Beckermann et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2017)
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors
Kiyonori Tanoue et al.
CANCER RESEARCH (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth et al.
CANCER RESEARCH (2016)
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Maarten A. Ligtenberg et al.
JOURNAL OF IMMUNOLOGY (2016)
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
Emilia Andersson et al.
ONCOIMMUNOLOGY (2016)
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Xiaojun Liu et al.
CANCER RESEARCH (2016)
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status
Yosra Messai et al.
EUROPEAN UROLOGY (2016)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
Frank A. Schildberg et al.
IMMUNITY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
Timothy M. Nywening et al.
LANCET ONCOLOGY (2016)
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Tessa Gargett et al.
MOLECULAR THERAPY (2016)
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Caroline Wigerup et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
Richard P. Junghans et al.
PROSTATE (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Kheng Newick et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice
Ava Vila-Leahey et al.
ONCOIMMUNOLOGY (2016)
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Soranobu Ninomiya et al.
BLOOD (2015)
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Rachel A. Burga et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Albert Lo et al.
CANCER RESEARCH (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
The Evolution of T-cell Therapies for Solid Malignancies
Kristen Fousek et al.
CLINICAL CANCER RESEARCH (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages
Takanori Kitamura et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Ignazio Caruana et al.
NATURE MEDICINE (2015)
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
Huimin Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model
Lei Wang et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Therapeutic use of anti-CTLA-4 antibodies
Christian U. Blank et al.
INTERNATIONAL IMMUNOLOGY (2015)
T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression
Stephen P. Santoro et al.
CANCER IMMUNOLOGY RESEARCH (2015)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
CD47 in the Tumor Microenvironment Limits Cooperation between Antitumor T-cell Immunity and Radiotherapy
David R. Soto-Pantoja et al.
CANCER RESEARCH (2014)
Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2014)
Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright et al.
CLINICAL CANCER RESEARCH (2014)
OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy
Yannick Bulliard et al.
IMMUNOLOGY AND CELL BIOLOGY (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor
Ann M. Leen et al.
MOLECULAR THERAPY (2014)
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Laura Bonapace et al.
NATURE (2014)
CXC chemokines and chemokine receptors in gastric cancer: From basic findings towards therapeutic targeting
Hyo Jin Lee et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
Liang-Chuan S. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
Stefani Spranger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy
L. Zhang et al.
GENE THERAPY (2013)
Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency
W. Wang et al.
GENE THERAPY (2013)
Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery
Xinping Fu et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia
Edward W. Roberts et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia
Eric Tran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
Petra C. Schuberth et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells
Yisheng Zheng et al.
MOLECULAR IMMUNOLOGY (2013)
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Sunitha Kakarla et al.
MOLECULAR THERAPY (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia
Joanna Baginska et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
Daisuke Sugiyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
Renier J. Brentjens et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients
D. Lorusso et al.
BRITISH JOURNAL OF CANCER (2012)
IL-4 induces proliferation in prostate cancer PC3 cells under nutrient-depletion stress through the activation of the JNK-pathway and survivin up-regulation
Hernan Roca et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
Arianna Calcinotto et al.
JOURNAL OF IMMUNOLOGY (2012)
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy
Jon G. Quatromoni et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma
Soranobu Ninomiya et al.
LEUKEMIA & LYMPHOMA (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy
Anna Johansson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133+Ovarian Cancer Stem-Like Cells via NF-?B-Mediated MMP-9 Upregulation
Haixia Long et al.
STEM CELLS (2012)
HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Wei-Hua Yan
Endocrine Metabolic & Immune Disorders-Drug Targets (2012)
Won't you come on in? How to favor lymphocyte infiltration in tumors
Matteo Bellone et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP
Soranobu Ninomiya et al.
ANNALS OF HEMATOLOGY (2011)
Chromogranin A Restricts Drug Penetration and Limits the Ability of NGR-TNF to Enhance Chemotherapeutic Efficacy
Eleonora Dondossola et al.
CANCER RESEARCH (2011)
Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
Edmund K. Moon et al.
CLINICAL CANCER RESEARCH (2011)
Chemokines as mediators of tumor angiogenesis and neovascularization
Ellen C. Keeley et al.
EXPERIMENTAL CELL RESEARCH (2011)
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Barbara Molon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Hypoxia-Dependent Inhibition of Tumor Cell Susceptibility to CTL-Mediated Lysis Involves NANOG Induction in Target Cells
Meriem Hasmim et al.
JOURNAL OF IMMUNOLOGY (2011)
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin-Zhi Qian et al.
NATURE (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Andrea Facciabene et al.
NATURE (2011)
Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance?
Leos Kren et al.
NEUROPATHOLOGY (2011)
Targeting hypoxia in cancer therapy
William R. Wilson et al.
NATURE REVIEWS CANCER (2011)
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
Jang-June Park et al.
BLOOD (2010)
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Xiangdong Liu et al.
BLOOD (2010)
Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
Rajeev K. Shrimali et al.
CANCER RESEARCH (2010)
5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
Julie Vincent et al.
CANCER RESEARCH (2010)
Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor beta-Insensitive CD8(+) T Cells
Longxin Wang et al.
CLINICAL CANCER RESEARCH (2010)
IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion
Vasilena Gocheva et al.
GENES & DEVELOPMENT (2010)
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice
Dhanalakshmi Chinnasamy et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
John A. Craddock et al.
JOURNAL OF IMMUNOTHERAPY (2010)
Induction of Lymphoidlike Stroma and Immune Escape by Tumors That Express the Chemokine CCL21
Jacqueline D. Shields et al.
SCIENCE (2010)
Targeting the tumour vasculature: insights from physiological angiogenesis
Alicia S. Chung et al.
NATURE REVIEWS CANCER (2010)
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
Antonio Di Stasi et al.
BLOOD (2009)
Therapeutic targeting of myeloid-derived suppressor cells
Stefano Ugel et al.
CURRENT OPINION IN PHARMACOLOGY (2009)
RGS5, a Hypoxia-inducible Apoptotic Stimulator in Endothelial Cells
Yi Jin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Myeloid-Derived Suppressor Cells Down-Regulate L-Selectin Expression on CD4+ and CD8+ T Cells
Erica M. Hanson et al.
JOURNAL OF IMMUNOLOGY (2009)
Selective accumulation of differentiated FOXP3+ CD4+ T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood
Camilla Jandus et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4
M. Todaro et al.
CELL DEATH AND DIFFERENTIATION (2008)
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor
Aaron E. Foster et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Juliana Hamzah et al.
NATURE (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Ronald J. Buckanovich et al.
NATURE MEDICINE (2008)
Tumor immune escape by the loss of homeostatic chemokine expression
Anclor Pivarcsi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
Yulia Nefedova et al.
CANCER RESEARCH (2007)
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity
Mary T. Litzinger et al.
BLOOD (2007)
Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4
Matilde Todaro et al.
CELL STEM CELL (2007)
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function
Paolo Serafini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF - Secreting cancer immunotherapy
Betty Li et al.
CLINICAL CANCER RESEARCH (2006)
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
Noweeda Mirza et al.
CANCER RESEARCH (2006)
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-β receptor
K Lacuesta et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Effects of the tumor vasculature targeting agent NGR-TNF on the tumor microenvironment in murine lymphomas
HWM van Laarhoven et al.
INVESTIGATIONAL NEW DRUGS (2006)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
eInterleukin-4 enhances proliferation of human pancreatic cancer cells: evidence for autocrine and paracrine actions
O Prokopchuk et al.
BRITISH JOURNAL OF CANCER (2005)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
TJ Curiel et al.
NATURE MEDICINE (2004)
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A(2A) receptors
MV Sitkovsky et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise
AJ Dannenberg et al.
CANCER CELL (2003)
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors
JB Rubin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2
MH Kershaw et al.
HUMAN GENE THERAPY (2002)
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection
M Friberg et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase
G Frumento et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors
TMJ Niederman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells
WP Zou et al.
NATURE MEDICINE (2001)
Involvement of chemokine receptors in breast cancer metastasis
A Müller et al.
NATURE (2001)
Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
B Almand et al.
JOURNAL OF IMMUNOLOGY (2001)
Enhancement of tumor necrosis factor a antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
F Curnis et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
